Serum concentration of interleukin 15, interleukin 2 receptor and TNF receptor in patients with polymyositis and dermatomyositis: correlation to disease activity

Cytokines are implied in polymyositis/dermatomyositis (PM/DM) pathogenesis. Our aim was to evaluate the serum levels of interleukin-15 (IL-15), soluble receptors for IL-2 (sIL-2R) and TNF-alpha type 1 receptor (sTNF-R1) in PM/DM patients and their relation to disease activity and clinical symptoms....

Full description

Saved in:
Bibliographic Details
Published inRheumatology international Vol. 32; no. 3; pp. 639 - 643
Main Authors Mielnik, Pawel, Chwalinska-Sadowska, Hanna, Wiesik-Szewczyk, Ewa, Maslinski, Wlodzimierz, Olesinska, Marzena
Format Journal Article
LanguageEnglish
Published Berlin/Heidelberg Springer-Verlag 01.03.2012
Springer Nature B.V
Subjects
Online AccessGet full text
ISSN0172-8172
1437-160X
1437-160X
DOI10.1007/s00296-010-1692-y

Cover

Loading…
Abstract Cytokines are implied in polymyositis/dermatomyositis (PM/DM) pathogenesis. Our aim was to evaluate the serum levels of interleukin-15 (IL-15), soluble receptors for IL-2 (sIL-2R) and TNF-alpha type 1 receptor (sTNF-R1) in PM/DM patients and their relation to disease activity and clinical symptoms. Thirty-eight patients who met definite or probable criteria of Bohan and Peter for DM/PM were included into the study. Results in patients with active (41 observations) and inactive disease (24 observations) were compared with control (15 subjects). The median level of IL-15 was 47.6 ± 170 pg/ml in active patients, 25.15 ± 240 pg/ml in inactive and 28.5 ± 28.89 pg/ml in controls. We demonstrated significant differences between active patients and controls in levels of IL-15 (0.016, 95%CI 1.39–57.1). The median level of sIL-2R was 314 ± 388, 235.3 ± 269 and 144.3 ± 152.9 pg/ml, and the median level of sTNF-R1 was 350 ± 388; 294.7 ± 204.7; 209.5 ± 105.9 pg/ml in active, inactive and control subjects, respectively. There were significantly higher serum levels of these cytokines in active patients than in control subjects (for sIL-2R P  = 0.05, CI95% 0.4–331; and sTNF-R1 P  = 0.031, CI95% 15.1–321.5). The interleukin levels did not differ between inactive patients and controls. Elevation of IL-15, sIL2-R and sTNF-R1 in active patients provides preliminary evidence for the activation of inflammatory response during PM/DM flares. Further studies may be needed to explain the mechanisms driving these diseases.
AbstractList Cytokines are implied in polymyositis/dermatomyositis (PM/DM) pathogenesis. Our aim was to evaluate the serum levels of interleukin-15 (IL-15), soluble receptors for IL-2 (sIL-2R) and TNF-alpha type 1 receptor (sTNF-R1) in PM/DM patients and their relation to disease activity and clinical symptoms. Thirty-eight patients who met definite or probable criteria of Bohan and Peter for DM/PM were included into the study. Results in patients with active (41 observations) and inactive disease (24 observations) were compared with control (15 subjects). The median level of IL-15 was 47.6 ± 170 pg/ml in active patients, 25.15 ± 240 pg/ml in inactive and 28.5 ± 28.89 pg/ml in controls. We demonstrated significant differences between active patients and controls in levels of IL-15 (0.016, 95%CI 1.39-57.1). The median level of sIL-2R was 314 ± 388, 235.3 ± 269 and 144.3 ± 152.9 pg/ml, and the median level of sTNF-R1 was 350 ± 388; 294.7 ± 204.7; 209.5 ± 105.9 pg/ml in active, inactive and control subjects, respectively. There were significantly higher serum levels of these cytokines in active patients than in control subjects (for sIL-2R P = 0.05, CI95% 0.4-331; and sTNF-R1 P = 0.031, CI95% 15.1-321.5). The interleukin levels did not differ between inactive patients and controls. Elevation of IL-15, sIL2-R and sTNF-R1 in active patients provides preliminary evidence for the activation of inflammatory response during PM/DM flares. Further studies may be needed to explain the mechanisms driving these diseases.
Cytokines are implied in polymyositis/dermatomyositis (PM/DM) pathogenesis. Our aim was to evaluate the serum levels of interleukin-15 (IL-15), soluble receptors for IL-2 (sIL-2R) and TNF-alpha type 1 receptor (sTNF-R1) in PM/DM patients and their relation to disease activity and clinical symptoms. Thirty-eight patients who met definite or probable criteria of Bohan and Peter for DM/PM were included into the study. Results in patients with active (41 observations) and inactive disease (24 observations) were compared with control (15 subjects). The median level of IL-15 was 47.6 ± 170 pg/ml in active patients, 25.15 ± 240 pg/ml in inactive and 28.5 ± 28.89 pg/ml in controls. We demonstrated significant differences between active patients and controls in levels of IL-15 (0.016, 95%CI 1.39–57.1). The median level of sIL-2R was 314 ± 388, 235.3 ± 269 and 144.3 ± 152.9 pg/ml, and the median level of sTNF-R1 was 350 ± 388; 294.7 ± 204.7; 209.5 ± 105.9 pg/ml in active, inactive and control subjects, respectively. There were significantly higher serum levels of these cytokines in active patients than in control subjects (for sIL-2R P  = 0.05, CI95% 0.4–331; and sTNF-R1 P  = 0.031, CI95% 15.1–321.5). The interleukin levels did not differ between inactive patients and controls. Elevation of IL-15, sIL2-R and sTNF-R1 in active patients provides preliminary evidence for the activation of inflammatory response during PM/DM flares. Further studies may be needed to explain the mechanisms driving these diseases.
Cytokines are implied in polymyositis/dermatomyositis (PM/DM) pathogenesis. Our aim was to evaluate the serum levels of interleukin-15 (IL-15), soluble receptors for IL-2 (sIL-2R) and TNF-alpha type 1 receptor (sTNF-R1) in PM/DM patients and their relation to disease activity and clinical symptoms. Thirty-eight patients who met definite or probable criteria of Bohan and Peter for DM/PM were included into the study. Results in patients with active (41 observations) and inactive disease (24 observations) were compared with control (15 subjects). The median level of IL-15 was 47.6 ± 170 pg/ml in active patients, 25.15 ± 240 pg/ml in inactive and 28.5 ± 28.89 pg/ml in controls. We demonstrated significant differences between active patients and controls in levels of IL-15 (0.016, 95%CI 1.39-57.1). The median level of sIL-2R was 314 ± 388, 235.3 ± 269 and 144.3 ± 152.9 pg/ml, and the median level of sTNF-R1 was 350 ± 388; 294.7 ± 204.7; 209.5 ± 105.9 pg/ml in active, inactive and control subjects, respectively. There were significantly higher serum levels of these cytokines in active patients than in control subjects (for sIL-2R P = 0.05, CI95% 0.4-331; and sTNF-R1 P = 0.031, CI95% 15.1-321.5). The interleukin levels did not differ between inactive patients and controls. Elevation of IL-15, sIL2-R and sTNF-R1 in active patients provides preliminary evidence for the activation of inflammatory response during PM/DM flares. Further studies may be needed to explain the mechanisms driving these diseases.Cytokines are implied in polymyositis/dermatomyositis (PM/DM) pathogenesis. Our aim was to evaluate the serum levels of interleukin-15 (IL-15), soluble receptors for IL-2 (sIL-2R) and TNF-alpha type 1 receptor (sTNF-R1) in PM/DM patients and their relation to disease activity and clinical symptoms. Thirty-eight patients who met definite or probable criteria of Bohan and Peter for DM/PM were included into the study. Results in patients with active (41 observations) and inactive disease (24 observations) were compared with control (15 subjects). The median level of IL-15 was 47.6 ± 170 pg/ml in active patients, 25.15 ± 240 pg/ml in inactive and 28.5 ± 28.89 pg/ml in controls. We demonstrated significant differences between active patients and controls in levels of IL-15 (0.016, 95%CI 1.39-57.1). The median level of sIL-2R was 314 ± 388, 235.3 ± 269 and 144.3 ± 152.9 pg/ml, and the median level of sTNF-R1 was 350 ± 388; 294.7 ± 204.7; 209.5 ± 105.9 pg/ml in active, inactive and control subjects, respectively. There were significantly higher serum levels of these cytokines in active patients than in control subjects (for sIL-2R P = 0.05, CI95% 0.4-331; and sTNF-R1 P = 0.031, CI95% 15.1-321.5). The interleukin levels did not differ between inactive patients and controls. Elevation of IL-15, sIL2-R and sTNF-R1 in active patients provides preliminary evidence for the activation of inflammatory response during PM/DM flares. Further studies may be needed to explain the mechanisms driving these diseases.
Cytokines are implied in polymyositis/dermatomyositis (PM/DM) pathogenesis. Our aim was to evaluate the serum levels of interleukin-15 (IL-15), soluble receptors for IL-2 (sIL-2R) and TNF-alpha type 1 receptor (sTNF-R1) in PM/DM patients and their relation to disease activity and clinical symptoms. Thirty-eight patients who met definite or probable criteria of Bohan and Peter for DM/PM were included into the study. Results in patients with active (41 observations) and inactive disease (24 observations) were compared with control (15 subjects). The median level of IL-15 was 47.6 ± 170 pg/ml in active patients, 25.15 ± 240 pg/ml in inactive and 28.5 ± 28.89 pg/ml in controls. We demonstrated significant differences between active patients and controls in levels of IL-15 (0.016, 95%CI 1.39-57.1). The median level of sIL-2R was 314 ± 388, 235.3 ± 269 and 144.3 ± 152.9 pg/ml, and the median level of sTNF-R1 was 350 ± 388; 294.7 ± 204.7; 209.5 ± 105.9 pg/ml in active, inactive and control subjects, respectively. There were significantly higher serum levels of these cytokines in active patients than in control subjects (for sIL-2R P = 0.05, CI95% 0.4-331; and sTNF-R1 P = 0.031, CI95% 15.1-321.5). The interleukin levels did not differ between inactive patients and controls. Elevation of IL-15, sIL2-R and sTNF-R1 in active patients provides preliminary evidence for the activation of inflammatory response during PM/DM flares. Further studies may be needed to explain the mechanisms driving these diseases.[PUBLICATION ABSTRACT]
Author Mielnik, Pawel
Olesinska, Marzena
Maslinski, Wlodzimierz
Chwalinska-Sadowska, Hanna
Wiesik-Szewczyk, Ewa
Author_xml – sequence: 1
  givenname: Pawel
  surname: Mielnik
  fullname: Mielnik, Pawel
  email: mielnik.p@gmail.com
  organization: Department of Connective Tissue Diseases, Institute of Rheumatology
– sequence: 2
  givenname: Hanna
  surname: Chwalinska-Sadowska
  fullname: Chwalinska-Sadowska, Hanna
  organization: Department of Connective Tissue Diseases, Institute of Rheumatology
– sequence: 3
  givenname: Ewa
  surname: Wiesik-Szewczyk
  fullname: Wiesik-Szewczyk, Ewa
  organization: Department of Connective Tissue Diseases, Institute of Rheumatology
– sequence: 4
  givenname: Wlodzimierz
  surname: Maslinski
  fullname: Maslinski, Wlodzimierz
  organization: Department of Pathophysiology and Immunology, Institute of Rheumatology
– sequence: 5
  givenname: Marzena
  surname: Olesinska
  fullname: Olesinska, Marzena
  organization: Department of Connective Tissue Diseases, Institute of Rheumatology
BackLink https://www.ncbi.nlm.nih.gov/pubmed/21132303$$D View this record in MEDLINE/PubMed
BookMark eNp9Ustu1TAQtVARvS18ABtksWHTgB-Jk7CohKoWkCpYcBfsLNuZtC6JHWynKJ_Dn-I2fdBKsLF1Zs45M2PPHtpx3gFCLyl5Swmp30VCWCsKQklBRcuK5Qna0JLXGZHvO2hDaM2KJh-7aC_GC5KxEOQZ2mWUcsYJ36Df3yDMIzbeGXApqGS9w77H1iUIA8w_rMO0OniAGQ5gYEo-YOU6vP1ych_I6SmbZK-If9l0jic_LOPio002XtM7CKNK_jb2PtcOAYa1cvK4sxFUBKxMspc2Lc_R014NEV7c3Ptoe3K8PfpUnH79-Pnow2lhStGkojam7irdV7UGIhRry0bQsu8bUxmjBS87gMooRUFr3mjT9Ep3pe76pq80UXwfHa6206xH6NbXGOQU7KjCIr2y8mHG2XN55i8lZy1tOM8Gb24Mgv85Q0xytNHAMCgHfo6yZYJWtG1FZr5-xLzwc3B5uEyq6qqt2iaTXv3dz10jt1-XCXQlmOBjDNDfUSiRV-sh1_WQ5Arn9ZBL1tSPNMam65fPI9nhv0q2KmOu4s4g3Pf8b9EfxGzV_A
CitedBy_id crossref_primary_10_1007_s13311_022_01220_z
crossref_primary_10_1182_blood_2014_01_550566
crossref_primary_10_1155_2020_6243019
crossref_primary_10_3109_03009742_2014_956141
crossref_primary_10_3390_cells12172192
crossref_primary_10_1371_journal_pone_0092171
crossref_primary_10_1007_s12016_016_8527_x
crossref_primary_10_1080_14397595_2021_1881027
crossref_primary_10_1007_s11926_011_0166_x
crossref_primary_10_18632_oncotarget_6462
crossref_primary_10_3390_biom13091345
crossref_primary_10_1136_annrheumdis_2014_205278
crossref_primary_10_1016_j_gene_2016_06_055
crossref_primary_10_3233_JND_170234
crossref_primary_10_3389_fimmu_2020_00037
crossref_primary_10_17795_gct_31087
crossref_primary_10_1155_2019_9141420
crossref_primary_10_1007_s10238_023_01155_5
crossref_primary_10_1016_j_semarthrit_2017_10_010
crossref_primary_10_1093_rheumatology_ket413
crossref_primary_10_1016_j_rmed_2018_06_012
crossref_primary_10_3390_ijms25063279
crossref_primary_10_3389_fimmu_2023_1053099
Cites_doi 10.1182/blood.V97.1.14
10.1093/rheumatology/36.6.656
10.1093/intimm/dxf062
10.1056/NEJM197502132920706
10.1016/0959-8049(95)00541-2
10.1007/s002960050111
10.1093/rheumatology/40.12.1398
10.1111/j.1600-0609.2006.00702.x
10.1007/s100670070027
10.1002/art.21249
10.1136/ard.61.suppl_2.ii100
10.4049/jimmunol.169.4.1760
ContentType Journal Article
Copyright The Author(s) 2010
Springer-Verlag 2012
Copyright_xml – notice: The Author(s) 2010
– notice: Springer-Verlag 2012
DBID C6C
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
88E
8AO
8FI
8FJ
8FK
ABUWG
AFKRA
BENPR
CCPQU
FYUFA
GHDGH
K9.
M0S
M1P
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOI 10.1007/s00296-010-1692-y
DatabaseName Springer Nature OA Free Journals
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest Pharma Collection
ProQuest Hospital Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central
ProQuest One Community College
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
Health & Medical Collection (Alumni)
Proquest Medical Database
ProQuest Central Premium
ProQuest One Academic
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Pharma Collection
ProQuest Central China
ProQuest Hospital Collection (Alumni)
ProQuest Central
ProQuest Health & Medical Complete
Health Research Premium Collection
ProQuest Medical Library
ProQuest One Academic UKI Edition
Health and Medicine Complete (Alumni Edition)
Health & Medical Research Collection
ProQuest Central (New)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Medical Library (Alumni)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE

MEDLINE - Academic

ProQuest One Academic Middle East (New)
Database_xml – sequence: 1
  dbid: C6C
  name: Springer Nature Open Access Journals
  url: http://www.springeropen.com/
  sourceTypes: Publisher
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: BENPR
  name: ProQuest One Academic
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1437-160X
EndPage 643
ExternalDocumentID PMC3291833
2600027191
21132303
10_1007_s00296_010_1692_y
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
-53
-5E
-5G
-BR
-EM
-Y2
-~C
.86
.GJ
.VR
06C
06D
0R~
0VY
123
199
1N0
1SB
2.D
203
28-
29P
29~
2J2
2JN
2JY
2KG
2KM
2LR
2P1
2VQ
2~H
30V
36B
3V.
4.4
406
408
409
40D
40E
53G
5QI
5RE
5VS
67Z
6NX
78A
7X7
88E
8AO
8FI
8FJ
8TC
8UJ
95-
95.
95~
96X
AAAVM
AABHQ
AACDK
AAHNG
AAIAL
AAJBT
AAJKR
AANXM
AANZL
AARHV
AARTL
AASML
AATNV
AATVU
AAUYE
AAWCG
AAYIU
AAYQN
AAYTO
AAYZH
ABAKF
ABBBX
ABBXA
ABDZT
ABECU
ABFTV
ABHLI
ABHQN
ABIPD
ABJNI
ABJOX
ABKCH
ABKTR
ABMNI
ABMQK
ABNWP
ABPLI
ABQSL
ABSXP
ABTEG
ABTKH
ABTMW
ABULA
ABUWG
ABWNU
ABXPI
ACAOD
ACBXY
ACDTI
ACGFS
ACHSB
ACHXU
ACKNC
ACMDZ
ACMLO
ACOKC
ACOMO
ACPIV
ACUDM
ACZOJ
ADBBV
ADHHG
ADHIR
ADIMF
ADINQ
ADJJI
ADKNI
ADKPE
ADRFC
ADTPH
ADURQ
ADYFF
ADZKW
AEBTG
AEFIE
AEFQL
AEGAL
AEGNC
AEJHL
AEJRE
AEKMD
AEMSY
AENEX
AEOHA
AEPYU
AESKC
AETLH
AEVLU
AEXYK
AFBBN
AFEXP
AFKRA
AFLOW
AFQWF
AFWTZ
AFZKB
AGAYW
AGDGC
AGGDS
AGJBK
AGMZJ
AGQEE
AGQMX
AGRTI
AGWIL
AGWZB
AGYKE
AHAVH
AHBYD
AHIZS
AHMBA
AHSBF
AHYZX
AIAKS
AIGIU
AIIXL
AILAN
AITGF
AJBLW
AJRNO
AJZVZ
AKMHD
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ALWAN
AMKLP
AMXSW
AMYLF
AMYQR
AOCGG
ARMRJ
ASPBG
AVWKF
AXYYD
AZFZN
B-.
BA0
BBWZM
BDATZ
BENPR
BGNMA
BPHCQ
BSONS
BVXVI
C6C
CAG
CCPQU
COF
CS3
CSCUP
DDRTE
DL5
DNIVK
DPUIP
DU5
EBD
EBLON
EBS
EIOEI
EJD
EMB
EMOBN
EN4
ESBYG
F5P
FEDTE
FERAY
FFXSO
FIGPU
FINBP
FNLPD
FRRFC
FSGXE
FWDCC
FYUFA
G-Y
G-Z
GGCAI
GGRSB
GJIRD
GNWQR
GQ6
GQ7
GQ8
GRRUI
GXS
H13
HF~
HG5
HG6
HMCUK
HMJXF
HQYDN
HRMNR
HVGLF
HZ~
I09
IHE
IJ-
IKXTQ
IMOTQ
IWAJR
IXC
IXD
IXE
IZIGR
IZQ
I~X
I~Z
J-C
J0Z
JBSCW
JCJTX
JZLTJ
KDC
KOV
KOW
KPH
L7B
LAS
LLZTM
M1P
M4Y
MA-
N2Q
N9A
NB0
NDZJH
NPVJJ
NQJWS
NU0
O9-
O93
O9G
O9I
O9J
OAM
P19
P9S
PF0
PQQKQ
PROAC
PSQYO
PT4
PT5
Q2X
QOK
QOR
QOS
R4E
R89
R9I
RHV
RIG
RNI
RNS
ROL
RPX
RRX
RSV
RZK
S16
S1Z
S26
S27
S28
S37
S3B
SAP
SCLPG
SDE
SDH
SDM
SHX
SISQX
SJYHP
SMD
SNE
SNPRN
SNX
SOHCF
SOJ
SPISZ
SRMVM
SSLCW
SSXJD
STPWE
SV3
SZ9
SZN
T13
T16
TSG
TSK
TSV
TT1
TUC
U2A
U9L
UG4
UKHRP
UOJIU
UTJUX
UZXMN
VC2
VFIZW
W23
W48
WJK
WK8
YLTOR
Z45
Z7U
Z82
Z83
Z87
Z8O
Z8V
Z8W
Z91
ZGI
ZMTXR
ZOVNA
~A9
~EX
AAPKM
AAYXX
ABBRH
ABDBE
ABFSG
ACSTC
ADHKG
AEZWR
AFDZB
AFHIU
AFOHR
AGQPQ
AHPBZ
AHWEU
AIXLP
ATHPR
AYFIA
CITATION
PHGZM
PHGZT
ABRTQ
CGR
CUY
CVF
ECM
EIF
NPM
PJZUB
PPXIY
7XB
8FK
K9.
PKEHL
PQEST
PQUKI
PRINS
7X8
5PM
ID FETCH-LOGICAL-c468t-7cc7d5bf57be06a2948614ff8c5ccb634dee5caa1ebb38bc8fabd4bdf8f5b0a3
IEDL.DBID 7X7
ISSN 0172-8172
1437-160X
IngestDate Thu Aug 21 13:53:28 EDT 2025
Wed Jul 30 11:31:47 EDT 2025
Fri Jul 25 03:06:50 EDT 2025
Mon Jul 21 06:03:46 EDT 2025
Thu Apr 24 23:06:10 EDT 2025
Tue Jul 01 03:37:51 EDT 2025
Fri Feb 21 02:39:52 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 3
Keywords Interleukin-15
Polymyositis
Disease activity
Dermatomyositis
Language English
License This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c468t-7cc7d5bf57be06a2948614ff8c5ccb634dee5caa1ebb38bc8fabd4bdf8f5b0a3
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 14
ObjectType-Article-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://link.springer.com/10.1007/s00296-010-1692-y
PMID 21132303
PQID 925759598
PQPubID 326313
PageCount 5
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_3291833
proquest_miscellaneous_926151996
proquest_journals_925759598
pubmed_primary_21132303
crossref_primary_10_1007_s00296_010_1692_y
crossref_citationtrail_10_1007_s00296_010_1692_y
springer_journals_10_1007_s00296_010_1692_y
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2012-03-01
PublicationDateYYYYMMDD 2012-03-01
PublicationDate_xml – month: 03
  year: 2012
  text: 2012-03-01
  day: 01
PublicationDecade 2010
PublicationPlace Berlin/Heidelberg
PublicationPlace_xml – name: Berlin/Heidelberg
– name: Germany
– name: Heidelberg
PublicationSubtitle Clinical and Experimental Investigations
PublicationTitle Rheumatology international
PublicationTitleAbbrev Rheumatol Int
PublicationTitleAlternate Rheumatol Int
PublicationYear 2012
Publisher Springer-Verlag
Springer Nature B.V
Publisher_xml – name: Springer-Verlag
– name: Springer Nature B.V
References Liew, McInnes (CR9) 2002; 61
Franczuk, Szepietowski, Noworolska (CR12) 2004; 12
Kurowska, Rudnicka, Kontny, Janicka, Chorazy, Kowalczewski (CR8) 2002; 169
Holzer, Pfandlsteiner, Blahovec, Trieb, Kotz (CR17) 2003; 23
Shimizu, Tomita, Son, Nishinarita, Sawada, Horie (CR14) 2000; 19
Horak, Hermanova, Ordeltova, Faltynek, Kusa, Budikova (CR11) 2004; 50
Suzuki, Morimoto, Amano, Tokano, Takasaki, Hashimoto (CR3) 2001; 28
Viac, Vincent, Palacio, Schmitt, Claudy (CR16) 1996; 32A
Elkayam, Yaron, Shirazi, Yaron, Caspi (CR4) 2000; 19
Fujii, Nojima, Yasuoka, Satoh, Nakamura, Kuwana (CR13) 2001; 40
Goto, Tsurumi, Takemura, Hara, Sawada, Kasahara (CR15) 2006; 77
Tesarova, Kvasnicka, Umlaufova, Homolkova, Jirsa, Tesar (CR18) 2000; 6
Bohan, Peter (CR7) 1975; 292
Chrobak, Podzimek, Pliskova, Kerekes, Zak, Voglova (CR5) 1996; 43
Samsonov, Nassonov, Tilz, Geht, Demel, Gurkina (CR6) 1997; 36
Sugiura, Harigai, Kawaguchi, Takagi, Fukasawa, Ohsako-Higami (CR2) 2002; 14
Fehniger, Caligiuri (CR1) 2001; 97
Baslund, Tvede, Danneskiold-Samsoe, Larsson, Panayi, Petersen (CR10) 2005; 52
FY Liew (1692_CR9) 2002; 61
J Viac (1692_CR16) 1996; 32A
A Franczuk (1692_CR12) 2004; 12
T Fujii (1692_CR13) 2001; 40
N Goto (1692_CR15) 2006; 77
L Chrobak (1692_CR5) 1996; 43
J Suzuki (1692_CR3) 2001; 28
P Horak (1692_CR11) 2004; 50
T Sugiura (1692_CR2) 2002; 14
G Holzer (1692_CR17) 2003; 23
A Bohan (1692_CR7) 1975; 292
M Kurowska (1692_CR8) 2002; 169
TA Fehniger (1692_CR1) 2001; 97
MY Samsonov (1692_CR6) 1997; 36
O Elkayam (1692_CR4) 2000; 19
B Baslund (1692_CR10) 2005; 52
T Shimizu (1692_CR14) 2000; 19
P Tesarova (1692_CR18) 2000; 6
References_xml – volume: 97
  start-page: 14
  year: 2001
  end-page: 32
  ident: CR1
  article-title: Interleukin 15: biology and relevance to human disease
  publication-title: Blood
  doi: 10.1182/blood.V97.1.14
– volume: 61
  start-page: 100
  issue: S2
  year: 2002
  end-page: 102
  ident: CR9
  article-title: Role of interleukin 15 and interleukin 18 in inflammatory response
  publication-title: Ann Rheum Dis
– volume: 6
  start-page: 661
  year: 2000
  end-page: 667
  ident: CR18
  article-title: Soluble TNF and IL-2 receptors in patients with breast cancer
  publication-title: Med Sci Monit
– volume: 50
  start-page: 422
  year: 2004
  end-page: 427
  ident: CR11
  article-title: Neopterin and a soluble interleukin-2 receptor in patients with systemic lupus erythematodes
  publication-title: Vnitr Lek
– volume: 36
  start-page: 656
  year: 1997
  end-page: 660
  ident: CR6
  article-title: Elevated serum levels of neopterin in adult patients with polymyositis/dermatomyositis
  publication-title: Br J Rheumatol
  doi: 10.1093/rheumatology/36.6.656
– volume: 14
  start-page: 917
  year: 2002
  end-page: 924
  ident: CR2
  article-title: N.Increased IL-15 production of muscle cells in polymyositis and dermatomyositis
  publication-title: Int Immunol
  doi: 10.1093/intimm/dxf062
– volume: 292
  start-page: 344
  year: 1975
  end-page: 347
  ident: CR7
  article-title: Polymyositis and dermatomyositis (first of two parts)
  publication-title: N Engl J Med
  doi: 10.1056/NEJM197502132920706
– volume: 32A
  start-page: 447
  year: 1996
  end-page: 449
  ident: CR16
  article-title: Tumour necrosis factor (TNF) soluble receptors in malignant melanoma: correlation with soluble ICAM-1 levels
  publication-title: Eur J Cancer
  doi: 10.1016/0959-8049(95)00541-2
– volume: 19
  start-page: 101
  year: 2000
  end-page: 105
  ident: CR4
  article-title: Serum levels of IL-10, IL-6, IL-1ra, and sIL-2R in patients with psoriatic arthritis
  publication-title: Rheumatol Int
  doi: 10.1007/s002960050111
– volume: 40
  start-page: 1398
  year: 2001
  end-page: 1404
  ident: CR13
  article-title: Cytokine and immunogenetic profiles in Japanese patients with adult Still’s disease. Association with chronic articular disease
  publication-title: Rheumatology (Oxford)
  doi: 10.1093/rheumatology/40.12.1398
– volume: 169
  start-page: 1760
  year: 2002
  end-page: 1767
  ident: CR8
  article-title: Fibroblast-like synoviocytes from rheumatoid arthritis patients express functional IL-15 receptor complex: endogenous IL-15 in autocrine fashion enhances cell proliferation and expression of Bcl-x(L) and Bcl-2
  publication-title: J Immunol
– volume: 12
  start-page: 71
  year: 2004
  end-page: 76
  ident: CR12
  article-title: Serum concentrations of interleukin-2 soluble receptor (IL-2 sR) in patients with vitiligo: relationship with type and extent of the disease
  publication-title: Acta Dermatovenerol Croat
– volume: 28
  start-page: 2389
  year: 2001
  end-page: 2391
  ident: CR3
  article-title: Serum levels of interleukin 15 in patients with rheumatic diseases
  publication-title: J Rheumatol
– volume: 77
  start-page: 217
  year: 2006
  end-page: 225
  ident: CR15
  article-title: Serum-soluble tumor necrosis factor receptor 2 (sTNF-R2) level determines clinical outcome in patients with aggressive non-Hodgkin’s lymphoma
  publication-title: Eur J Haematol
  doi: 10.1111/j.1600-0609.2006.00702.x
– volume: 43
  start-page: 321
  year: 1996
  end-page: 325
  ident: CR5
  article-title: Serum soluble IL-2 receptor as a reliable and noninvasive marker of disease activity in patients with hairy cell leukemia
  publication-title: Neoplasma
– volume: 23
  start-page: 3057
  year: 2003
  end-page: 3059
  ident: CR17
  article-title: Serum levels of TNF-beta and sTNF-R in patients with malignant bone tumors
  publication-title: Anticancer Res
– volume: 19
  start-page: 352
  year: 2000
  end-page: 359
  ident: CR14
  article-title: Elevation of serum soluble tumour necrosis factor receptors in patients with polymyositis and dermatomyositis
  publication-title: Clin Rheumatol
  doi: 10.1007/s100670070027
– volume: 52
  start-page: 2686
  year: 2005
  end-page: 2692
  ident: CR10
  article-title: Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study
  publication-title: Arthritis Rheum
  doi: 10.1002/art.21249
– volume: 97
  start-page: 14
  year: 2001
  ident: 1692_CR1
  publication-title: Blood
  doi: 10.1182/blood.V97.1.14
– volume: 12
  start-page: 71
  year: 2004
  ident: 1692_CR12
  publication-title: Acta Dermatovenerol Croat
– volume: 61
  start-page: 100
  issue: S2
  year: 2002
  ident: 1692_CR9
  publication-title: Ann Rheum Dis
  doi: 10.1136/ard.61.suppl_2.ii100
– volume: 32A
  start-page: 447
  year: 1996
  ident: 1692_CR16
  publication-title: Eur J Cancer
  doi: 10.1016/0959-8049(95)00541-2
– volume: 43
  start-page: 321
  year: 1996
  ident: 1692_CR5
  publication-title: Neoplasma
– volume: 292
  start-page: 344
  year: 1975
  ident: 1692_CR7
  publication-title: N Engl J Med
  doi: 10.1056/NEJM197502132920706
– volume: 14
  start-page: 917
  year: 2002
  ident: 1692_CR2
  publication-title: Int Immunol
  doi: 10.1093/intimm/dxf062
– volume: 52
  start-page: 2686
  year: 2005
  ident: 1692_CR10
  publication-title: Arthritis Rheum
  doi: 10.1002/art.21249
– volume: 28
  start-page: 2389
  year: 2001
  ident: 1692_CR3
  publication-title: J Rheumatol
– volume: 40
  start-page: 1398
  year: 2001
  ident: 1692_CR13
  publication-title: Rheumatology (Oxford)
  doi: 10.1093/rheumatology/40.12.1398
– volume: 19
  start-page: 352
  year: 2000
  ident: 1692_CR14
  publication-title: Clin Rheumatol
  doi: 10.1007/s100670070027
– volume: 36
  start-page: 656
  year: 1997
  ident: 1692_CR6
  publication-title: Br J Rheumatol
  doi: 10.1093/rheumatology/36.6.656
– volume: 77
  start-page: 217
  year: 2006
  ident: 1692_CR15
  publication-title: Eur J Haematol
  doi: 10.1111/j.1600-0609.2006.00702.x
– volume: 50
  start-page: 422
  year: 2004
  ident: 1692_CR11
  publication-title: Vnitr Lek
– volume: 23
  start-page: 3057
  year: 2003
  ident: 1692_CR17
  publication-title: Anticancer Res
– volume: 169
  start-page: 1760
  year: 2002
  ident: 1692_CR8
  publication-title: J Immunol
  doi: 10.4049/jimmunol.169.4.1760
– volume: 6
  start-page: 661
  year: 2000
  ident: 1692_CR18
  publication-title: Med Sci Monit
– volume: 19
  start-page: 101
  year: 2000
  ident: 1692_CR4
  publication-title: Rheumatol Int
  doi: 10.1007/s002960050111
SSID ssj0017660
Score 2.0918922
Snippet Cytokines are implied in polymyositis/dermatomyositis (PM/DM) pathogenesis. Our aim was to evaluate the serum levels of interleukin-15 (IL-15), soluble...
SourceID pubmedcentral
proquest
pubmed
crossref
springer
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 639
SubjectTerms Adult
Biomarkers - blood
Dermatomyositis - blood
Dermatomyositis - complications
Dermatomyositis - diagnosis
Female
Humans
Interleukin-15 - blood
Lung Diseases, Interstitial - blood
Lung Diseases, Interstitial - complications
Lung Diseases, Interstitial - diagnosis
Male
Medicine
Medicine & Public Health
Middle Aged
Original
Original Article
Receptors, Interleukin-2 - blood
Receptors, Tumor Necrosis Factor, Type I - blood
Rheumatology
Skin Diseases - blood
Skin Diseases - complications
Skin Diseases - diagnosis
SummonAdditionalLinks – databaseName: SpringerLink Journals (ICM)
  dbid: U2A
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1La9wwEB7SFEovoY-0cdMWHXJqK_DKkmz3FkqWUEhOG8jNSLJEQzf2sus97M_JP-2MV3bYpC3kYIOkkWUzeszneQGc5EabMvOe117WXLq85kYrw43NCkeZrSaWgOLFpT6_kj-v1XX0414N1u6DSrLfqUdnN1IgEfpN-USXgm-ewXNF0B0n8ZU4HVUHue5dgwnb8AJvgyrzb4_YPYweSZiPDSUfaEv7Q2j6Cg6i9MhOt-x-DXu-eQMvLqJ-_C3c4dJf3zJHvohNDIjL2sAoKMRy7te_bxo2Ud92yoLhpucXiL2ZaWo2u5zeV2BzDLy6YvTHli3a-eZ20xt6rXrymnb2rh3qvuPYy2U0sGNdy6ICiJH_BKWpOITZ9Gz245zHJAzcSV10PHfIP2WDyq1PtRGlLPBED6FwyjmrM1l7r5wxE2-RvdYVwdha2joUQdnUZO9gv2kbfwTMSysdXlaLIF3QpTU5CiA-kyogMBUJpAMzKhcDlFOejHk1hlbu-VelVEb-VZsEvoxdFtvoHP8jPh44XMWFuqpKQRlKVVkkwMZWXGGkNjGNb9dEQlIf4sIE3m-nwzgWoucMMVyWQL4zUUYCCt6929Lc_OqDeGeixN0Ue34dptT9S_3zEz48ifoYXqJ4J7YWcx9hv1uu_ScUoTr7uV8yfwDyeRrr
  priority: 102
  providerName: Springer Nature
Title Serum concentration of interleukin 15, interleukin 2 receptor and TNF receptor in patients with polymyositis and dermatomyositis: correlation to disease activity
URI https://link.springer.com/article/10.1007/s00296-010-1692-y
https://www.ncbi.nlm.nih.gov/pubmed/21132303
https://www.proquest.com/docview/925759598
https://www.proquest.com/docview/926151996
https://pubmed.ncbi.nlm.nih.gov/PMC3291833
Volume 32
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwELdgkxAvaHxng8kPPAEWqWM7CS-oVC0TaBVCnVSeItuxtYkuKW360D-H_5S71MlUJvaQRPGHkujs853vl98R8ibVSueJc6x0omTCpiXTSmqmTZJZzGw1MOgonk_V2YX4OpfzgM1ZB1hlpxNbRV3WFvfIP-QcU0nKPPu0_M0waRQGV0MGjfvkEJnLENGVznt_C6kP2y0WWKNZBqcuqBm3HKIc0bcITVA5Z9v9ZemWrXkbMvlP3LRdjiZH5FGwI-lwJ_jH5J6rnpAH5yFS_pT8ASWwuaYW_0qsAjUurT1FeojVwm1-XVV0IN_v3XMK6s8twQunuirpbDq5KYDqQMG6prh3S5f1Ynu9bSFf67Z5iTq-qbuyj_Ds1SpA7WhT0xAKovgnBSaseEZmk_FsdMZCOgZmhcoallqQpDRepsbFSvNcZLC2e59Zaa1RiSidk1brgTMgaGMzr00pTOkzL02sk-fkoKor95JQJ4ywcBjFvbBe5UanYIq4REgPLiqPSNwJo7CBqhwzZiyKnmS5lV8R4z3Ir9hG5G3fZbnj6bir8Ukn4SJM2XXRD7CI0L4W5hoGUHTl6g02QfsPPMSIvNgNh_5Z4Ecn4M0lEUn3BkrfAGm892uqq8uWzjvhOehV6PmuG1I3L_XfTzi-8xNOyEMw7PgOK_eKHDSrjXsNxlNjTtspckoOh19-fhvD9fN4-v0HlI7UCM4XfPgX8p4img
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lj9MwEB4tXQm4IN6U5eEDXICI1HGcBAkhHlt12W2FUJH2FtmOI1Z0k9KmQvk53PmRzCROVmXF3vbQSomdxNGMx_Nlxt8APIuUVElgrZdZkXnCRJmnZKg8pYPYUGWrkSagOJ3JyTfx-Tg83oE_3V4YSqvsbGJjqLPS0Dfy1wmnUpJhEr9b_vSoaBQFV7sKGq1WHNr6FyK29duDTyje55yP9-cfJ54rKuAZIePKiwyOJ9R5GGnrS8UTEeMKleexCY3RMhCZtaFRamQ1DlebOFc6EzrL4zzUvgrwtldgVwQIZAaw-2F_9uVrH7WIZLMrmWCVF-NfF0X1G9JSTum-lAshE-7V2-vgOef2fI7mP4HaZv0b34QbznFl71tNuwU7trgNV6cuNH8HfqPV2ZwyQ9sgC8fFy8qcER_FamE3P04KNgpfbR1zhvbWLhH2M1VkbD4bn53AZsf5umb0sZgty0V9Wjc5Zuume0aLSlV2597gs1crl9vHqpK52BOjrRtUIeMuzC9DVPdgUJSFfQDMCi0M_rTkuTC5TLSK0PexgQhzxMR8CH4njNQ4bnQq0bFIe1bnRn6pT8cov7Qewov-kmVLDHJR571OwqmzEeu01-ghsL4VJzdFbFRhyw11IYcTIekQ7rfq0D8LgXuA8DEYQrSlKH0H4g3fbilOvjf84QFP0JDjlS87lTob1H9f4eGFr_AUrk3m06P06GB2uAfX0avkbaLeIxhUq419jJ5bpZ-4CcMgveQp-hesp19p
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELZKkSouqDy7lIcPcAGsZh07DySEEGXVUrrisEh7i2zHFhXbZJvNCuXn8C_4ecwkTqqlorceEimxkziah2c8428IeRmrSKWhtSy3ImfCxDlTkVRM6TAxWNlqrNFRPJ1GR9_Fl7mcb5E__V4YTKvsdWKrqPPS4Br5QcqxlKRMkwPnsyK-HU4-LC8YFpDCQGtfTaPjkBPb_ALvbfX--BBI_YrzyefZpyPmCwwwI6KkZrGBsUntZKxtECmeigRmK-cSI43RUShya6VRamw1DF2bxCmdC527xEkdqBBee4vcjkM5RgmL54Orh6iL7eoOmAcsgVMfTw1a-FKOib-YFRGlnDWbM-IVM_dqtuY_Idt2JpzskrvehKUfO567R7ZscZ_snPog_QPyG_TP-pwa3BBZeFReWjqKyBTVwq5_nhV0LN9uXHMKmtcu67KiqsjpbDq5vAHNHv11RXHZmC7LRXPetNlmq7Z7jtNLXfb33sG3q8pn-dG6pD4KRXETB9bKeEhmN0GoR2S7KAu7R6gVWhg4dMSdMC5KtYrBCrKhkA68Yz4iQU-MzHiUdCzWscgGfOeWflmA10C_rBmR18Mjyw4i5LrO-z2FM68tVtnA2yNCh1YQc4zdqMKWa-yCpic4pyPyuGOH4VvgwofgSIYjEm8wytABEcQ3W4qzHy2SeMhTUOnw5JuepS4H9d9feHLtL7wgOyCY2dfj6ck-uQPmJe8y9p6S7bpa22dgwtX6eSstlGQ3LJ1_AbN5Yjk
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Serum+concentration+of+interleukin+15%2C+interleukin+2+receptor+and+TNF+receptor+in+patients+with+polymyositis+and+dermatomyositis%3A+correlation+to+disease+activity&rft.jtitle=Rheumatology+international&rft.au=Mielnik%2C+Pawel&rft.au=Chwalinska-Sadowska%2C+Hanna&rft.au=Wiesik-Szewczyk%2C+Ewa&rft.au=Maslinski%2C+Wlodzimierz&rft.date=2012-03-01&rft.pub=Springer-Verlag&rft.issn=0172-8172&rft.eissn=1437-160X&rft.volume=32&rft.issue=3&rft.spage=639&rft.epage=643&rft_id=info:doi/10.1007%2Fs00296-010-1692-y&rft_id=info%3Apmid%2F21132303&rft.externalDocID=PMC3291833
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0172-8172&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0172-8172&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0172-8172&client=summon